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recurrence avoided is €82 in the 5 years time horizon and the
open mesh is the dominant option in the 15 years time horizon
from a hospital perspective. Results in the probability sensitivity
analysis are very similar to deterministic analysis. CONCLU-
SION: Findings suggest open mesh hernia repair method as a
very cost effective therapy from both hospitals and payers per-
spectives for the inguinal hernia treatment in Slovakia.
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OBJECTIVE: Operating rooms (OR) are an expensive hospital
resource. As a new selective reversal binding agent, sugammadex
has been shown in clinical trials to reduce reversal time (time
from reversal agent administration to full recovery) among
patients receiving selected steroidal neuromuscular-blocking
agents (NMBAs). Our goal was to develop a hospital efﬁciency
model to assess the potential impact of sugammadex adoption on
OR time. METHODS: A deterministic model was developed to
estimate potential time savings associated with sugammadex
adoption for the U.S. setting. Model inputs included surgical
caseloads, utilization rates of NMBAs and reversal strategies, OR
time components, and OR labor costs. The effects of reversal
strategies on reversal time were evaluated using clinical trial data.
Other model inputs were estimated using published literature
and analyses of secondary hospital databases. OR time saved was
deﬁned as the difference in minutes required for all procedures
performed per day in one OR before and after the introduction of
sugammadex. Estimates of savings in OR staff costs (including
OR nurse, OR technician, and certiﬁed registered nurse anesthe-
tist) were generated under alternative assumptions about the
likelihood that overtime is paid. Sensitivity analyses were per-
formed on key model assumptions. RESULTS: In the base-case
scenario, OR time saved by sugammadex was estimated to be
25 minutes per OR day or 612 hours annually in a typical US
hospital with 6 ORs. Associated annual cost savings were esti-
mated to range from $32,035 (25% of days involve overtime) to
$96,105 (75% of days involve overtime). Findings also varied
with the assumed adoption rate of sugammadex and hourly OR
staff salaries. CONCLUSION: Sugammadex may save OR time
and associated costs for U.S. hospitals, primarily by reducing
overtime pay. The net ﬁnancial beneﬁt of sugammadex will
depend on its cost and its adoption rate in clinical practice.
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OBJECTIVE: Deep vein thrombosis (DVT) and pulmonary
embolism (PE), collectively known as venous thromboembolism
(VTE), are well-known complications of total knee or hip
arthroplasty (TKA and THA). This study examined the eco-
nomic burden of VTE in arthroplasty surgeries from a US hos-
pital perspective. METHODS: Patients at least 18 years old
undergoing TKA and THA from January 1, 2002 to December
30, 2006 were extracted from a large, nationwide inpatient
database. Rates of events, length of hospital stay, inpatient costs
and reimbursed amounts (available for a small subset that could
be linked to managed care data) were evaluated. Multivariate
analyses were conducted on hospital costs to adjust for differ-
ences in demographic and clinical characteristics. RESULTS:
Out of 259,524 hip and knee surgeries (mean age of 67 years),
1.0% of patients diagnosed with VTE during hospitalization
(0.6% DVT only and 0.4% PE [with or without DVT]). Com-
pared to patients without VTE, mean length of stay (LOS) for
those with VTE was twice as long (8 vs. 4, p < 0.0001) and
hospital costs were 48.0% higher ($20,850 vs. $14,092,
p < 0.0001). Within the limited subset that had linked managed
care claims data (n = 5002), mean cost of patients with VTE
was 23.5% higher ($16,877 vs. $13,662, p < 0.0023); however,
the amount reimbursed was on average 6.4% higher ($14,121
vs. $13,272, p = 0.77). After multivariate adjustment, DVT
increased costs by $1421 following TKA and $3950 following
THA; PE increased costs by $2862 following TKA and $4355
following THA (p < 0.0001 for all). CONCLUSION: Experi-
encing VTE complications substantially adds to the costs of
TKA or THA. The increased hospital costs of patients with VTE
did not appear to be adequately reimbursed. The overall eco-
nomic impact of implementing prophylaxis to prevent VTE
events can be projected.
HEALTH CARE INTERVENTIONS—
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OBJECTIVE: The objective of this project was to review pub-
lished studies on quality of life (QoL) in animals. METHODS:
An electronic search in EMBASE including MEDLINE using
the key words “quality of life” and “animals” resulted in 1588
articles. Inclusion criteria for review was study on QoL, exclu-
sion criteria were case studies with n < 3, and studies in labora-
tory animals as proxy for humans. RESULTS: A total of 48
studies were included for review, of which 40 were performed in
dogs. The aim of nine studies was the development and valida-
tion of a questionnaire, three studies provided a checklist or
background information on QoL in animals. In the remaining 36
studies QoL was assessed as outcome measure in speciﬁc diseases
or treatments; however 30 of these studies were uncontrolled.
Previously developed, used or validated questionnaires were
included in only 3 studies. In 23 studies assessment of QoL was
limited to one single question, addressed to the owners. In 30 of
the 36 studies the evaluation of QoL was performed only at one
time point after the start of an intervention, of which 3 studies
retrospectively evaluated a baseline value. In 19 studies, all or
part of the animals were already dead at the time of assessment.
In 19 of the 30 uncontrolled studies QoL was rated as good to
excellent (or equivalent in scores) in >50% of the animals, even
in studies on severe conditions such as cancer or chemotherapy.
CONCLUSION: Most of the studies assessing QoL as outcome
used unvalidated questionnaires and included only one single
question addressed to the owners. It is questionable whether the
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